Saxagliptin and dapagliflozin and Xenleta (Lefamulin Tablets)
Determining the interaction of Saxagliptin and dapagliflozin and Xenleta (Lefamulin Tablets) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor. When oral midazolam was administered concomitantly with and at 2 or 4 hours after administration of lefamulin tablets, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 100% and 200%, respectively. No clinically significant differences in the pharmacokinetics of midazolam were observed when administered concomitantly with lefamulin injection. MANAGEMENT: Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever oral lefamulin is added to or withdrawn from therapy. References "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Professional:MONITOR: When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor. When oral midazolam was administered concomitantly with and at 2 or 4 hours after administration of lefamulin tablets, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 100% and 200%, respectively. No clinically significant differences in the pharmacokinetics of midazolam were observed when administered concomitantly with lefamulin injection.
MANAGEMENT: Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever oral lefamulin is added to or withdrawn from therapy.
- "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Generic Name: dapagliflozin / saxagliptin
Brand name: Qtern
Synonyms: Dapagliflozin and saxagliptin, Dapagliflozin and Saxagliptin
Generic Name: lefamulin
Brand name: Xenleta
Synonyms: Xenleta (Lefamulin Injection), Xenleta, Xenleta (oral/injection)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Saxagliptin and dapagliflozin-Xeomin
- Saxagliptin and dapagliflozin-Xerava
- Saxagliptin and dapagliflozin-Xerese
- Saxagliptin and dapagliflozin-Xerese Cream
- Saxagliptin and dapagliflozin-Xermelo
- Saxagliptin and dapagliflozin-Xgeva
- Xenleta (Lefamulin Tablets)-Saxagliptin and Metformin
- Xenleta (Lefamulin Tablets)-Saxagliptin Hydrochloride
- Xenleta (Lefamulin Tablets)-Saxenda
- Xenleta (Lefamulin Tablets)-Scalacort
- Xenleta (Lefamulin Tablets)-Scalacort DK
- Xenleta (Lefamulin Tablets)-Scalpcort